161 related articles for article (PubMed ID: 29479845)
21. ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
Cihan YB; Ozturk A; Arslan A; Deniz K; Baran M; Karaca H
Asian Pac J Cancer Prev; 2014; 15(10):4117-23. PubMed ID: 24935356
[TBL] [Abstract][Full Text] [Related]
22. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
[TBL] [Abstract][Full Text] [Related]
23. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
[TBL] [Abstract][Full Text] [Related]
24. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
[TBL] [Abstract][Full Text] [Related]
25. [Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].
Desoubeaux N; Bouvier V; Gervais R; Galateau-Salle F; Thibon P; Leplumey T; Herbert C; Lecherbonnier Y; Daviet JP; Letourneux M
Rev Epidemiol Sante Publique; 2001 Dec; 49(6):523-9. PubMed ID: 11845101
[TBL] [Abstract][Full Text] [Related]
26. [Malignant pleural mesothelioma: 2013 state of the art].
Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
[TBL] [Abstract][Full Text] [Related]
27. Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France.
Serrier H; Sultan-Taieb H; Luce D; Bejean S
Eur J Health Econ; 2014 Jul; 15(6):661-73. PubMed ID: 23974964
[TBL] [Abstract][Full Text] [Related]
28. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
29. National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
Saddoughi SA; Abdelsattar ZM; Blackmon SH
Ann Thorac Surg; 2018 Feb; 105(2):432-437. PubMed ID: 29223422
[TBL] [Abstract][Full Text] [Related]
30. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
31. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
32. Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.
Keshava HB; Tang A; Siddiqui HU; Raja S; Raymond DP; Bribriesco A; Stevenson J; Murthy SC; Ahmad U
World J Surg; 2019 Dec; 43(12):3239-3247. PubMed ID: 31428834
[TBL] [Abstract][Full Text] [Related]
33. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
Remon J; Nadal E; Dómine M; Ruffinelli J; García Y; Pardo JC; López R; Cilleruelo A; García-Campelo R; Martín P; Juan O; González-Larriba JL; Provencio M; Olmedo E; Ponce S; Cumplido D; Barenys C; Majem M; Massutti B; Rodriguez-Abreu D; Porta R; Sala MA; Martinez-Kareaga M; Lianes P; Reguart N
Lung Cancer; 2020 Sep; 147():83-90. PubMed ID: 32682189
[TBL] [Abstract][Full Text] [Related]
34. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
[TBL] [Abstract][Full Text] [Related]
35. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
[TBL] [Abstract][Full Text] [Related]
36. Patterns of care and survival among patients with malignant mesothelioma in the United States.
Enewold L; Sharon E; Thomas A
Lung Cancer; 2017 Oct; 112():102-108. PubMed ID: 29191582
[TBL] [Abstract][Full Text] [Related]
37. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
39. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.
Abdel-Rahman O
Strahlenther Onkol; 2017 Apr; 193(4):276-284. PubMed ID: 28044200
[TBL] [Abstract][Full Text] [Related]
40. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
